Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has revealed that the US approval of Ambien CR, the controlled-release formulation of the world's leading sleep aid, will be delayed as the FDA has asked for more information in an approvable letter for the drug.
Subscribe to our email newsletter
An approvable letter outlines specific questions that have to be resolved before the FDA will approve a product for marketing. The FDA’s questions in this letter relate specifically to Ambien CR (zolpidem tartrate extended release) and are not related to the safety and efficacy of the company’s insomnia treatment Ambien (zolpidem tartrate).
Sanofi-Aventis said that it is now working closely with the FDA to address the questions outlined in the letter.
The company’s blockbuster drug Ambien is indicated for the short-term treatment of insomnia and is marketed under the brand name Stilnox in Europe and as Myslee in Japan.
Sanofi-Aventis’ shares dipped by more than 1.5% in after-hours trading on the New York Stock Exchange following the news.